The emerging role of apelin, RAAS, and ACE2 crosstalk in pulmonary hypertension

apelin、RAAS 和 ACE2 串扰在肺动脉高压中的新作用

• 批准号: 10674620
• 负责人: Andrea Lee Frump
• 金额: $ 78万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-01 至 2027-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10674620
• 关键词: ACE2; APLN gene; Agonist; Angiotensin-Converting Enzyme Inhibitors; Blood Vessels; Cardiac; Cardiac Myocytes; Cells; Cessation of life; Clinical; Data; Development; Disease; Drug Delivery Systems; Endothelial Cells; Experimental Models; Functional disorder; Goals; Heart; Human; Impairment; Industry; Link; Lung; Mediating; Mediator; Mission; Modeling; Molecular; National Heart, Lung, and Blood Institute; Nuclear; Nuclear Receptors; Oral; Outcome; Pathway interactions; Patient Rights; Patients; Peptides; Peptidyl-Dipeptidase A; Public Health; Publishing; Pulmonary Heart Disease; Pulmonary Hypertension; Pulmonary Vascular Resistance; Pulmonary artery structure; Renin-Angiotensin-Aldosterone System; Research; Right Ventricular Function; Rodent Model; Role; Signal Pathway; Signal Transduction; Testing; Therapeutically Targetable; Tissues; Vasodilation; Ventricular; Work; angiogenesis; heart function; improved; in vivo; induced pluripotent stem cell; interest; mortality; novel; prevent; protective effect; pulmonary artery endothelial cell; pulmonary vascular remodeling; pulmonary vasoconstriction; receptor; receptor-mediated signaling; right ventricular failure; right ventricular remodeling; targeted treatment; treatment strategy

PROJECT SUMMARY This proposal builds on the scientific premise that right ventricular (RV) maladaptive remodeling is a major contributor to RV failure and mortality in pulmonary hypertension (PH). Despite its importance, no RV-directed therapies exist. The goal of this proposal is to is to identify 1) whether Apelin prevents RV failure and 2) whether Apelin-mediated protection is dependent on abrogation of RAAS and activation of ACE2. We provide evidence that treatment with Apelin can prevent ventricular-vascular uncoupling in vivo. We also provide evidence in human induced pluripotent stem cell cardiomyocytes (iPSC-SMs), RV-specific endothelial cells (RVECs), and pulmonary artery endothelial cells (PAECs) that treatment with Apelin increases the expression of Angiotensin- converting enzyme (ACE2) and decreases the expression of Renin-Angiotensin-Aldosterone System (RAAS) signaling mediator ACE1, potentially linking these pathways. Intriguingly, our evidence also demonstrates that 1) Apelin and ACE2 are decreased in PH models and cells 2) ACE1 is increased, and 3) Apelin receptor nuclear localization in control but not PH patient RV tissue and cells, suggesting a possible mechanism of action. However, the interaction between these pathways during RV failure and whether Apelin-mediated RV adaptation is dependent on enhancement of ACE2 signaling remains elusive. Based on these findings, we put forward the hypothesis that Apelin signaling abrogates PH-induced RV-pulmonary artery (PA) uncoupling by inhibiting RAAS and enhancing ACE2 signaling. To test our hypothesis, we propose the following aims: 1) To determine if Apelin receptor-mediated signaling promotes RV adaptative remodeling and survival through the inhibition of RAAS and activation of ACE2 2) To demonstrate that impaired nuclear localization of the Apelin receptor (APLNR) contributes to RV failure and PH development 3) To identify whether Apelin-mediated inhibition of RAAS and enhancement of ACE2 abrogates pulmonary vascular remodeling. The proposed studies are significant; they will ascertain whether Apelin is a critical mediator of RV adaptive remodeling in PH, which if true, may establish a novel and therapeutically targetable Apelin-mediated signaling axis in the RV. Targeting Apelin signaling is of particular importance: inhibition of RAAS signaling has led to mixed clinical outcomes in PH patients and drug delivery of ACE2 remains a substantial challenge. In contrast, recent industry interest has led to the development of several orally deliverable Apelin/APLNR agonists, therefore, if Apelin protection against PH is dependent on RAAS inhibition and enhancement of ACE2 in the RV and pulmonary vasculature, it would provide the rationale to use these novel Apelin/APLNR agonists to target RAAS, ACE2 and treat PH. Upon completion of the proposed studies, we will have demonstrated that by leveraging the Apelin signaling pathway, we can promote RV adaptive remodeling. Identification of pathways and targets engaged by Apelin during RV failure will allow for the development of novel, long-acting and targeted treatment strategies for the PA-RV circuit.

项目摘要 该建议建立在右心室（RV）适应不良重构是一个主要的 在肺动脉高压（PH）中，RV衰竭和死亡率的贡献者。尽管它的重要性，没有RV指导 治疗是存在的。本提案的目标是确定1）Apelin是否可预防RV衰竭，以及2）是否 Apelin介导的保护作用依赖于RAAS的消除和ACE 2的激活。我们提供的证据 用Apelin治疗可以防止体内心室-血管解偶联。我们还提供了证据， 人诱导多能干细胞心肌细胞（iPSC-SM）、RV特异性内皮细胞（RVEC）和 用Apelin处理的肺动脉内皮细胞（PAEC）增加血管紧张素- 血管紧张素转换酶2（ACE 2）和降低肾素-血管紧张素-醛固酮系统（RAAS）的表达 信号传导介质ACE 1，可能连接这些途径。有趣的是，我们的证据还表明， 1)在PH模型和细胞中，Apelin和ACE 2减少; 2）ACE 1增加; 3）Apelin受体核 在对照而不是PH患者RV组织和细胞中的定位，表明可能的作用机制。 然而，在RV衰竭期间这些通路之间的相互作用以及Apelin是否介导RV适应， 依赖于ACE 2信号的增强仍然是难以捉摸的。基于这些发现，我们提出了 Apelin信号通过抑制RAAS消除PH诱导的RV-肺动脉（PA）解偶联的假说 和增强ACE 2信号传导。为了验证我们的假设，我们提出了以下目标：1）确定Apelin是否 受体介导的信号通过抑制RAAS促进RV适应性重塑和存活 2）为了证明Apelin受体（APLNR）的受损核定位， 3）为了确定爱帕琳蛋白介导的RAAS抑制和 ACE 2的增强消除了肺血管重构。这些研究成果意义重大，它们 将确定Apelin是否是PH中RV适应性重塑的关键介质，如果是真的， RV中一种新的治疗靶向Apelin介导的信号传导轴。靶向Apelin信号传导是 特别重要的是：RAAS信号传导的抑制导致PH患者和药物治疗的临床结果混合 ACE 2的递送仍然是一个重大挑战。相比之下，最近的行业兴趣导致了发展 因此，如果Apelin对PH的保护依赖于 RAAS抑制和增强RV和肺血管中的ACE 2，这将提供理论基础 使用这些新的Apelin/APLNR激动剂靶向RAAS、ACE 2和治疗PH。 研究，我们将证明，通过利用Apelin信号通路，我们可以促进RV适应性 重塑RV衰竭期间Apelin参与的通路和靶点的识别将允许 为PA-RV回路开发新型、长效和靶向治疗策略。

项目成果

Pathophysiology and new advances in pulmonary hypertension.

• DOI: 10.1136/bmjmed-2022-000137
• 发表时间: 2023
• 期刊: BMJ medicine
• 作者: Bousseau, Simon;Fais, Rafael Sobrano;Gu, Sue;Frump, Andrea;Lahm, Tim
• 通讯作者: Lahm, Tim